vs
艾伯维（ABBV）与Enhabit, Inc.（EHAB）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Enhabit, Inc.的61.5倍（$16.6B vs $270.4M）。艾伯维净利率更高（10.9% vs -14.3%，领先25.2%）。艾伯维同比增速更快（10.0% vs 4.7%）。艾伯维自由现金流更多（$4.9B vs $3.3M）。过去两年艾伯维的营收复合增速更高（16.2% vs 1.5%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
Enhabit, Inc.是总部位于美国得克萨斯州达拉斯的居家护理与临终关怀服务提供商，目前在全美34个州运营255个居家护理站点与110个临终关怀站点，业务集中在得克萨斯、亚拉巴马、佛罗里达、佐治亚、俄克拉荷马与密西西比，是美国第四大居家护理服务商，也是头部临终关怀服务商，2022年由恩compass健康拆分居家护理与临终关怀业务拆分成立。
ABBV vs EHAB — 直观对比
营收规模更大
ABBV
是对方的61.5倍
$270.4M
营收增速更快
ABBV
高出5.3%
4.7%
净利率更高
ABBV
高出25.2%
-14.3%
自由现金流更多
ABBV
多$4.9B
$3.3M
两年增速更快
ABBV
近两年复合增速
1.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $270.4M |
| 净利润 | $1.8B | $-38.7M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 27.3% | -12.3% |
| 净利率 | 10.9% | -14.3% |
| 营收同比 | 10.0% | 4.7% |
| 净利润同比 | 8354.5% | 15.9% |
| 每股收益（稀释后） | $1.02 | $-0.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVEHAB
| Q4 25 | $16.6B | $270.4M | ||
| Q3 25 | $15.8B | $263.6M | ||
| Q2 25 | $15.4B | $266.1M | ||
| Q1 25 | $13.3B | $259.9M | ||
| Q4 24 | $15.1B | $258.2M | ||
| Q3 24 | $14.5B | $253.6M | ||
| Q2 24 | $14.5B | $260.6M | ||
| Q1 24 | $12.3B | $262.4M |
净利润ABBVEHAB
| Q4 25 | $1.8B | $-38.7M | ||
| Q3 25 | $186.0M | $11.1M | ||
| Q2 25 | $938.0M | $5.2M | ||
| Q1 25 | $1.3B | $17.8M | ||
| Q4 24 | $-22.0M | $-46.0M | ||
| Q3 24 | $1.6B | $-110.2M | ||
| Q2 24 | $1.4B | $-200.0K | ||
| Q1 24 | $1.4B | $200.0K |
毛利率ABBVEHAB
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
营业利润率ABBVEHAB
| Q4 25 | 27.3% | -12.3% | ||
| Q3 25 | 12.1% | 6.4% | ||
| Q2 25 | 31.7% | 6.3% | ||
| Q1 25 | 28.0% | 6.1% | ||
| Q4 24 | -9.9% | -16.0% | ||
| Q3 24 | 26.5% | -38.6% | ||
| Q2 24 | 27.6% | 4.3% | ||
| Q1 24 | 22.7% | 4.9% |
净利率ABBVEHAB
| Q4 25 | 10.9% | -14.3% | ||
| Q3 25 | 1.2% | 4.2% | ||
| Q2 25 | 6.1% | 2.0% | ||
| Q1 25 | 9.6% | 6.8% | ||
| Q4 24 | -0.1% | -17.8% | ||
| Q3 24 | 10.8% | -43.5% | ||
| Q2 24 | 9.5% | -0.1% | ||
| Q1 24 | 11.1% | 0.1% |
每股收益（稀释后）ABBVEHAB
| Q4 25 | $1.02 | $-0.76 | ||
| Q3 25 | $0.10 | $0.22 | ||
| Q2 25 | $0.52 | $0.10 | ||
| Q1 25 | $0.72 | $0.35 | ||
| Q4 24 | $-0.03 | $-0.92 | ||
| Q3 24 | $0.88 | $-2.20 | ||
| Q2 24 | $0.77 | $0.00 | ||
| Q1 24 | $0.77 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $43.6M |
| 总债务越低越好 | $58.9B | $426.0M |
| 股东权益账面价值 | $-3.3B | $534.0M |
| 总资产 | $134.0B | $1.2B |
| 负债/权益比越低杠杆越低 | — | 0.80× |
8季度趋势，按日历期对齐
现金及短期投资ABBVEHAB
| Q4 25 | $5.3B | $43.6M | ||
| Q3 25 | $5.7B | $56.9M | ||
| Q2 25 | $6.5B | $37.1M | ||
| Q1 25 | $5.2B | $39.5M | ||
| Q4 24 | $5.6B | $28.4M | ||
| Q3 24 | $7.3B | $45.7M | ||
| Q2 24 | $13.2B | $28.5M | ||
| Q1 24 | $18.1B | $36.5M |
总债务ABBVEHAB
| Q4 25 | $58.9B | $426.0M | ||
| Q3 25 | $63.0B | $441.5M | ||
| Q2 25 | $63.0B | $456.9M | ||
| Q1 25 | $64.5B | $467.3M | ||
| Q4 24 | $60.3B | $492.6M | ||
| Q3 24 | $58.5B | $502.9M | ||
| Q2 24 | $58.0B | $512.7M | ||
| Q1 24 | $63.8B | $526.7M |
股东权益ABBVEHAB
| Q4 25 | $-3.3B | $534.0M | ||
| Q3 25 | $-2.6B | $566.8M | ||
| Q2 25 | $-183.0M | $552.4M | ||
| Q1 25 | $1.4B | $543.2M | ||
| Q4 24 | $3.3B | $523.5M | ||
| Q3 24 | $6.0B | $566.1M | ||
| Q2 24 | $6.8B | $674.3M | ||
| Q1 24 | $8.0B | $672.3M |
总资产ABBVEHAB
| Q4 25 | $134.0B | $1.2B | ||
| Q3 25 | $133.9B | $1.2B | ||
| Q2 25 | $137.2B | $1.2B | ||
| Q1 25 | $136.2B | $1.2B | ||
| Q4 24 | $135.2B | $1.2B | ||
| Q3 24 | $143.4B | $1.3B | ||
| Q2 24 | $141.9B | $1.4B | ||
| Q1 24 | $148.9B | $1.4B |
负债/权益比ABBVEHAB
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | 45.44× | 0.86× | ||
| Q4 24 | 18.15× | 0.94× | ||
| Q3 24 | 9.70× | 0.89× | ||
| Q2 24 | 8.56× | 0.76× | ||
| Q1 24 | 7.97× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $4.4M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $3.3M |
| 自由现金流率自由现金流/营收 | 29.4% | 1.2% |
| 资本支出强度资本支出/营收 | 2.0% | 0.4% |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | $65.8M |
8季度趋势，按日历期对齐
经营现金流ABBVEHAB
| Q4 25 | $5.2B | $4.4M | ||
| Q3 25 | $7.0B | $37.8M | ||
| Q2 25 | $5.2B | $10.6M | ||
| Q1 25 | $1.6B | $17.9M | ||
| Q4 24 | $7.0B | $-4.1M | ||
| Q3 24 | $5.4B | $28.4M | ||
| Q2 24 | $2.3B | $9.6M | ||
| Q1 24 | $4.0B | $17.3M |
自由现金流ABBVEHAB
| Q4 25 | $4.9B | $3.3M | ||
| Q3 25 | $6.6B | $36.2M | ||
| Q2 25 | $4.9B | $8.7M | ||
| Q1 25 | $1.4B | $17.6M | ||
| Q4 24 | $6.8B | $-4.7M | ||
| Q3 24 | $5.2B | $27.7M | ||
| Q2 24 | $2.0B | $8.9M | ||
| Q1 24 | $3.8B | $15.5M |
自由现金流率ABBVEHAB
| Q4 25 | 29.4% | 1.2% | ||
| Q3 25 | 42.1% | 13.7% | ||
| Q2 25 | 31.7% | 3.3% | ||
| Q1 25 | 10.5% | 6.8% | ||
| Q4 24 | 44.7% | -1.8% | ||
| Q3 24 | 35.9% | 10.9% | ||
| Q2 24 | 14.0% | 3.4% | ||
| Q1 24 | 31.3% | 5.9% |
资本支出强度ABBVEHAB
| Q4 25 | 2.0% | 0.4% | ||
| Q3 25 | 2.4% | 0.6% | ||
| Q2 25 | 1.7% | 0.7% | ||
| Q1 25 | 1.8% | 0.1% | ||
| Q4 24 | 1.9% | 0.2% | ||
| Q3 24 | 1.7% | 0.3% | ||
| Q2 24 | 1.7% | 0.3% | ||
| Q1 24 | 1.6% | 0.7% |
现金转化率ABBVEHAB
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | 3.41× | ||
| Q2 25 | 5.49× | 2.04× | ||
| Q1 25 | 1.27× | 1.01× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | 86.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
